entertainment -WSS

entertainment

author：comprehensive 2025-09-30 04:34:50 - browse：54

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Medicare has a new plan to address drug shortages

knowledge

WSS

Custom gene therapy hints at new path for rare disease treatments

AI can’t replace a physician’s gut feeling

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Listen: Wegovy in the brain & pivotal Alzheimer's data

Pharma patents targeted by Biden in move to slash drug prices

In early work, researchers turn to CRISPR to treat Alzheimer's

hotspot

entertainment

focus

In age of alternative facts, a scholarly course on calling out crap

How dance can help nurses traumatized by Covid

Walensky prepares to leave CDC — and Congress — behind

Chemotherapy shortages won’t get better under Biden’s latest plan

After affirmative action ruling, medical educators look to 'holistic review'

Key House panel plots a new health care package

BioMarin wins approval for gene therapy to treat hemophilia A

FDA approves world's first CRISPR

Hepatitis C has a cure — but many Americans still lack access to it

At Orexo, a ‘turning point’ for everything but digital health

focus

In diabetes hearing, Sanders takes on a new foe: food makers

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

In diabetes hearing, Sanders takes on a new foe: food makers

Supreme Court wrestles with OxyContin maker's bankruptcy deal

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

In diabetes hearing, Sanders takes on a new foe: food makers

Wikipedia

knowledge

explore

focus